{"id":"hb-as02v","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HB-AS02V combines hepatitis B surface antigen with an adjuvant system to enhance immunogenicity and promote both cellular and humoral immune responses. The vaccine is intended to generate protective antibodies and T-cell responses against hepatitis B virus, potentially for use in chronic hepatitis B patients or as a preventive vaccine.","oneSentence":"HB-AS02V is a therapeutic vaccine designed to stimulate immune responses against hepatitis B surface antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:40.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"Hepatitis B prevention"}]},"trialDetails":[{"nctId":"NCT00445185","phase":"PHASE3","title":"Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™","status":"COMPLETED","sponsor":"Henogen","startDate":"2007-03","conditions":"Hepatitis B","enrollment":102},{"nctId":"NCT00291954","phase":"PHASE3","title":"Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination","status":"COMPLETED","sponsor":"Henogen","startDate":"2006-03","conditions":"Hepatitis B","enrollment":257},{"nctId":"NCT00291980","phase":"PHASE3","title":"A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.","status":"COMPLETED","sponsor":"Henogen","startDate":"2006-03","conditions":"Hepatitis B","enrollment":185}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HB-AS02V","genericName":"HB-AS02V","companyName":"Henogen","companyId":"henogen","modality":"Biologic","firstApprovalDate":"","aiSummary":"HB-AS02V is a therapeutic vaccine designed to stimulate immune responses against hepatitis B surface antigen. Used for Chronic hepatitis B infection, Hepatitis B prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}